| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Marek's disease virus modified for the expression of NDV-F protein
Record information and status
Record ID
Date of creation
2009-06-20 19:36 UTC (manoela.miranda@cbd.int)
Date of last update
2015-01-26 17:19 UTC (dina.abdelhakim@cbd.int)
Date of publication
2015-01-26 17:19 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Marek's disease virus modified for the expression of NDV-F protein
Transformation event
Cellmune N
Akinobu Funatsu
Director General
The Chemo-Sero-Therapeutic Research Institute
1-6-1 Okubo, Kumamoto-shi, Kumamoto 860-8568, Japan
Recombinant Marek's disease virus (a.k.a Gallid herpesvirus 2) modified to express NDV-F protein gene to generate a vaccine that helps aid in the protection against Newcastle and Marek's diseases in poultry.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Gallid alphaherpesvirus 2
Point of collection or acquisition of the recipient organism
Marek's disease virus serotype 1 strain 207
Characteristics of the transformation process
Techniques used for the modification
  • Electroporation
Genetic elements construct
Glycoprotein B promoter
0.50 Kb
Fusion protein gene
0.00 Kb
Transcription termination factor
0.25 Kb
Further details
Notes regarding the genetic elements introduced or modified in this LMO
An insertion plasmid called pKA4BPF was engineered by cloning an expression cassette composed of gB promoter, F protein gene and transcription termination factor into the commercially available plasmid vector pUC119 and used for the development of the recombinant virus.

The gB promoter was used with the aim of effectively expressing the NDV-F protein gene (see below) in the cells infected with MDV1. It is known that the homologous UL28 of HSV1 functions by incorporating the virus DNA into viral particles. However, it is not known how the protein encoded by UL28 functions in MDV1.

Homologous recombination was conducted by transferring the insertion vector plasmid pKA4BPF into a chicken embryo primary cell line infected with the MDV1 CVI988 C17 strain, the recipient organism virus, based on electroporation.

The gB (glycoprotein B) promoter region was cloned from the CVI988 C17 strain of the Gallid herpesvirus 2. It is a 0.5kb fragment amplified through PCR, with the EcoRI site added at each 5' end. The gB promoter sequence is configured mostly with the 3'-terminal of UL28 gene, containing 20% of its ORFs.

NDV-F gene derived from the avirulent Newcastle disease virus (NDV) D26 strain.

Transcription termination factor is a 0.25kb fragment derived from the commercially available expression plasmid pSVL. It contains the polyA addition signal and also the 3'-terminal sequence (77 bases) of large T antigen ORF of SV40 and the 3'-terminal sequence (61 bases) of VP1, the major virus capsid.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Other relevant website address or attached documents

Records referencing this document (1)
1record(s) found
Risk Assessment1 record